Document is current
Any future updates will be listed below
-
Authors
Fløde, Mari
Hermann, Monica
Igland, Jannicke
Hernar, Ingvild
Sigurdardottir, Arun K.
Søfteland, Eirik
Åsberg, Anders
Jenssen, Trond Geir
Haugstvedt, Anne
-
Funding
Funding for this research was provided by:
Western Norway University Of Applied Sciences
- License Information
-
More Information
Article History
Received: 19 June 2025
Accepted: 3 November 2025
First Online: 15 December 2025
Declarations
:
: The study protocol was approved by the Regional Committee for Medical and Health Research Ethics (REK South-East) (2018/512). This research project was conducted in accordance with the Helsinki Declaration. Each participant was informed about the study protocol and provided a written and informed consent form before taking part in the study.
: Not applicable.
: Mari Fløde has received lecture fees from Novo Nordisk and Abbott. Ingvild Hernar has received lecture fees from Novo Nordisk. Trond Geir Jenssen has received lecture fees from Novo Nordisk, Eli Lilly, Astra Zeneca and Boehringen Ingelheim. Eirik Søfteland has received lecture fees from Novo Nordisk, Boehringen Ingelheim, Astra Zeneca, Otsuko Pharma, Eli Lilly and Sanof Aventis. Anne Haugstvedt has received lecture fees from Novo Nordisk and Abbott. Other authors declared no competing interests.
